The Lancet Diabetes & Endocrinology, 7 (11), 834-844
it raised a $53M Series A led by Andreessen Horowitz's Bio + Health practice in 2024 and a $298M Series B in November 2025 a signal of how much capital believes in measurement-first health.20,21 Superpower (founded 2023, Los Angeles) competes on price and software, offering 100+ biomarkers near $199/year with stronger AI tooling, a care team, and prescription access.21,22 Lifeforce takes the clinician-led route quarterly testing, physician interpretation, and prescription pathways aimed squarely at midlife performance and hormonal optimization.21 The category matured enough to produce its first major lawsuit: in January 2026, Function Health sued Superpower over allegedly deceptive advertising, a dispute that turned, revealingly, on the question of what even counts as a "biomarker."20 The strategic point for a reader evaluating cognitive peptides: these companies have solved the measurement half of the equation and are racing on price and panel size
NAVES A
Thats a competitive moat strategy at industrial scale
MT-II is among the most stable at 30-40 days refrigerated
The frequency of glutathione injections can vary depending on individual health goals and the advice of a healthcare provider
